Purpose: The pharmacology, pharmacokinetics, clinical efficacy, adverse effects, drug interactions, and role in therapy of vildagliptin for the treatment of type 2 diabetes mellitus were reviewed.

Medically reviewed by Lindsay Cook, PharmD Type 2 diabetes is a form of diabetes characterized by high blood sugar (glucose), ...

Treatment for T2D typically begins with oral antidiabetic agents and a reduction in glycated haemoglobin A1c (HbA1c) — a reflection of glucose levels over the preceding 3 months — to below 7% ...

Sitagliptin (Januvia™) is a new oral agent approved by the US FDA to treat Type 2 diabetes. This is the first approved agent in a new class of antihyperglycemics, dipeptidyl peptidase (DPP)-4 ...

Merck & Co has been fighting to defend its blockbuster type 2 diabetes therapy Januvia from generic competition for years, and a new judgment looks set to protect its third biggest-selling drug ...

Bagsværd, Denmark Tuesday, April 1, 2025, 18:00 Hrs [IST] ...

Merck and Pfizer are to take on the crowded SGLT2 inhibitor market with a keenly-priced new contender. The FDA approved Steglatro (ertugliflozin) as a monotherapy in conjunction with diet and ...